35.15 -0.20 (-0.57%)
After hours: 5:14PM EST
|Bid||34.75 x 1400|
|Ask||36.40 x 1200|
|Day's Range||34.69 - 36.88|
|52 Week Range||2.14 - 52.55|
|Beta (3Y Monthly)||-0.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.36|
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid to $28.45 on November 20. Tandem Diabetes Care’s revenue rose an impressive 71.33% from $27.0 million in the third quarter of 2017 to $46.26 million in the third quarter of 2018. Tandem Diabetes incurred a net loss of $73.03 million in 2017.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
AQR Capital Management is a $226 billion global investment management firm launched back in 1998, by a guru in the financial world, billionaire Cliff Asness. Among other accomplishments, he became well regarded in the investing universe, thanks to his doctoral dissertation for which he closely studied the use of technical analysis to determine undervalued stocks. During […]
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.
For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.
Tandem Diabetes Care’s (TNDM) interest and other expenses fell from $2.93 million in the third quarter of 2017 to $1.40 million in the latest quarter. Tandem Diabetes Care’s net loss widened from $16.03 million in the third quarter of 2017 to $34.26 million in the latest quarter, which translated into a net loss per share of $0.62 in the third quarter of 2018. Its net loss per share was $3.09 in the third quarter of 2017. Tandem Diabetes Care stock rose significantly from $2.52 on January 5 to $51.17 on September 13, which was its high point for 2018.
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on pumps’ home screens. This is the only pump capable of remote feature updates on the US market. Tandem also sells disposable products such as cartridges and infusion sets that are used with its pumps and replaced periodically. In August 2018, Tandem began the commercialization of the t:slim X2 in key regions outside the United States.
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced that Kim Blickenstaff, President and Chief Executive Officer and Leigh Vosseller, EVP and Chief Financial Officer, will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, AZ at 12:20pm Eastern Time .
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced it has been named a top workplace in San Diego by The San Diego Union-Tribune and awarded a “Future Forward” 2018 Top Workplaces honor.
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced that management will present at the following upcoming inves
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
Kim Blickenstaff became the CEO of Tandem Diabetes Care Inc (NASDAQ:TNDM) in 2007. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at Read More...
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.
• Array BioPharma (ARRY) gained $1.16 to $16.20 Wednesday after posting quarterly results that topped Wall Street expectations. The move broke the stock out above key lateral resistance as it has emerged from a head-and-shoulders bottoming pattern. Volume of 6.5 million shares was the biggest for the drug developer since May when its stock last broke out.
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.